Table q1_q4_2023_prescription_drug_wac

Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like V*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992307501	Envarsus XR .75mg 100 Tab	Brand	FDA	06/23/2023	16.66	492.54	08/30/2028	Single Source Drug	13549780	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992307501	Envarsus XR .75mg 100 Tab	Brand	FDA	12/22/2023	9.85	502.39	08/30/2028	Single Source Drug	31741	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992307503	Envarsus XR .75mg 30 Tab	Brand	FDA	06/23/2023	5.00	147.77	08/30/2028	Single Source Drug	7342461	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992307503	Envarsus XR .75mg 30 Tab	Brand	FDA	12/22/2023	2.96	150.73	08/30/2028	Single Source Drug	54789	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992301001	Envarsus XR 1mg 100 Tab	Brand	FDA	06/23/2023	22.21	656.72	08/30/2028	Single Source Drug	91569047	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992301001	Envarsus XR 1mg 100 Tab	Brand	FDA	12/22/2023	13.13	669.85	08/30/2028	Single Source Drug	159730	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992301003	Envarsus XR 1mg 30 Tab	Brand	FDA	06/23/2023	6.66	197.02	08/30/2028	Single Source Drug	41272566	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992301003	Envarsus XR 1mg 30 Tab	Brand	FDA	12/22/2023	3.94	200.96	08/30/2028	Single Source Drug	231804	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992304001	Envarsus XR 4mg 100 Tab	Brand	FDA	06/23/2023	88.83	2626.83	08/30/2028	Single Source Drug	105699412	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992304001	Envarsus XR 4mg 100 Tab	Brand	FDA	12/22/2023	52.54	2679.37	08/30/2028	Single Source Drug	47258	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992304003	Envarsus XR 4mg 30 Tab	Brand	FDA	06/23/2023	26.65	788.05	08/30/2028	Single Source Drug	58188207	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992304003	Envarsus XR 4mg 30 Tab	Brand	FDA	12/22/2023	15.76	803.81	08/30/2028	Single Source Drug	82394	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000450	Vericel Corporation	09/30/2023	69866103005	MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 1 BAG in 1 BOX (69866-1030-5) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-4) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-3) Package Size 1 Quantity 1	Brand	FDA	07/01/2023	3919.00	56171.00	11/25/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-01. The product was relabeled and given a new NDC # 69866-1030-05 with a market entry date 05/10/2021.
Rx0000450	Vericel Corporation	09/30/2023	69866103008	MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6) Package Size 2 Package Quantity 1	Brand	FDA	07/01/2023	7838.00	112342.00	11/25/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-02. The product was relabeled and given a new NDC # 69866-1030-08 with a market entry date 05/10/2021.
Rx0000502	Viatris Specialty LLC	03/31/2023	00069781030	Caduet Tabs 10mg/10mg 30s	Brand	FDA	01/03/2023	34.25	523.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069216030	Caduet Tabs 10mg/10mg 30s (DC)	Brand	Medispan	01/03/2023	34.25	523.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00069-2160-30 is a discontinued NDC effective 08/31/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069218030	Caduet Tabs 10mg/20mg 30s	Brand	Medispan	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 01/27/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069225030	Caduet Tabs 10mg/40mg 30s	Brand	Medispan	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 01/18/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069227030	Caduet Tabs 10mg/80mg 30s	Brand	Medispan	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 01/18/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069215030	Caduet Tabs 5mg/10mg 30s	Brand	Medispan	01/03/2023	34.25	523.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 02/03/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069217030	Caduet Tabs 5mg/20mg 30s	Brand	Medispan	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 02/03/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069219030	Caduet Tabs 5mg/40mg 30s	Brand	Medispan	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069226030	Caduet Tabs 5mg/80mg 30s	Brand	FDA	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 01/27/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049241010	Cardura Tabs 1mg 100s	Brand	FDA	01/03/2023	37.63	575.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This NDC represents an NDC Change from the previous NDC: 00049-2750-66 (included within this report), and this NDC represents the new, updated NDC for the same product. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049275066	Cardura Tabs 1mg 100s (DC)	Brand	Medispan	01/03/2023	62.74	575.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-2750-66 is a discontinued NDC effective 10/19/2021 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049251210	Cardura Tabs 2mg 100s	Brand	FDA	01/03/2023	37.63	575.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049276066	Cardura Tabs 2mg 100s (DC)	Brand	Medispan	01/03/2023	62.74	575.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-2760-66 is a discontinued NDC effective 10/19/2021 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049261410	Cardura Tabs 4mg 100s	Brand	FDA	01/03/2023	39.49	603.66	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049277066	Cardura Tabs 4mg 100s (DC)	Brand	Medispan	01/03/2023	65.84	603.66	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-2770-66 is a discontinued NDC effective 10/19/2021 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049278066	Cardura Tabs 8mg 100s	Brand	Medispan	01/03/2023	41.47	633.90	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 02/15/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049204010	Cardura XL Tabs 4mg 30s	Brand	FDA	01/03/2023	12.98	198.35	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049271030	Cardura XL Tabs 4mg 30s (DC)	Brand	Medispan	01/03/2023	21.64	198.35	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-2710-30 is a discontinued NDC effective 01/21/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049208010	Cardura XL Tabs 8mg 30s	Brand	FDA	01/03/2023	13.63	208.37	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049272030	Cardura XL Tabs 8mg 30s (DC)	Brand	Medispan	01/03/2023	13.63	208.37	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-2720-30 is a discontinued NDC effective 04/26/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152031	Celebrex Caps 100mg 100s	Brand	FDA	01/03/2023	62.36	953.25	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152051	Celebrex Caps 100mg 500s	Brand	FDA	01/03/2023	311.82	4766.36	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152034	Celebrex Caps 100mg UD100	Brand	FDA	01/03/2023	62.36	953.25	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152531	Celebrex Caps 200mg 100s	Brand	FDA	01/03/2023	102.29	1563.59	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152551	Celebrex Caps 200mg 500s	Brand	FDA	01/03/2023	511.45	7817.91	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152534	Celebrex Caps 200mg UD100	Brand	FDA	01/03/2023	102.29	1563.59	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025153002	Celebrex Caps 400mg 60s	Brand	FDA	01/03/2023	92.07	1407.29	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025153001	Celebrex Caps 400mg UD100	Brand	FDA	01/03/2023	153.44	2345.44	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025151501	Celebrex Caps 50mg 60s	Brand	FDA	01/03/2023	17.49	267.29	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071036932	Dilantin ER Caps 100mg 1000s	Generic	FDA	01/03/2023	104.82	1602.31	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071036924	Dilantin ER Caps 100mg 100s	Generic	FDA	01/03/2023	10.48	160.24	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071036940	Dilantin ER Caps 100mg UD100	Generic	FDA	01/03/2023	11.57	176.82	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071374066	Dilantin ER Caps 30mg 100s	Generic	FDA	01/03/2023	9.04	138.16	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071000724	Dilantin Infatabs 50mg 100s	Generic	FDA	01/03/2023	9.82	150.14	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071000740	Dilantin Infatabs 50mg UD100	Generic	FDA	01/03/2023	13.93	212.95	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083621	Effexor XR Caps 150mg 30s	Brand	FDA	01/03/2023	39.02	596.42	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083622	Effexor XR Caps 150mg 90s	Brand	FDA	01/03/2023	117.05	1789.19	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083721	Effexor XR Caps 37.5mg 30s	Brand	FDA	01/03/2023	31.97	488.68	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083722	Effexor XR Caps 37.5mg 90s	Brand	FDA	01/03/2023	95.91	1466.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083321	Effexor XR Caps 75mg 30s	Brand	FDA	01/03/2023	35.82	547.54	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083322	Effexor XR Caps 75mg 90s	Brand	FDA	01/03/2023	107.47	1642.77	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049035260	Geodon Caps 20mg 60s	Brand	FDA	01/03/2023	93.25	1425.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049005260	Geodon Caps 20mg 60s (DC)	Brand	Medispan	01/03/2023	155.48	1425.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-0052-60 is a discontinued NDC effective 11/08/2021 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049005460	Geodon Caps 40mg 60s	Brand	Medispan	01/03/2023	93.25	1425.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049035660	Geodon Caps 60mg 60s	Brand	FDA	01/03/2023	113.16	1729.78	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049035860	Geodon Caps 80mg 60s	Brand	FDA	01/03/2023	113.16	1729.78	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049392083	Geodon Injection 20mg/mL SDV 10PK	Brand	FDA	01/03/2023	40.14	613.61	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049120310	Geodon Injection 20mg/mL SDV 10PK (Premier Pro)	Brand	Medispan	01/03/2023	66.93	613.61	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-1203-10 is a discontinued NDC effective 11/09/2021 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025171001	Inspra Tabs 25mg 30s	Brand	FDA	01/03/2023	27.64	422.45	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025171002	Inspra Tabs 25mg 90s	Brand	FDA	01/03/2023	82.91	1267.35	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 03/08/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025172003	Inspra Tabs 50mg 30s	Brand	FDA	01/03/2023	27.64	422.45	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025172001	Inspra Tabs 50mg 90s	Brand	FDA	01/03/2023	82.91	1267.35	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00025-1720-01 is a discontinued NDC effective 12/27/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071015892	Lipitor Tabs 80mg UD64	Brand	FDA	01/03/2023	77.38	1182.85	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00071-0158-92 is a discontinued NDC effective 12/27/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101568	Lyrica Caps 100mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101541	Lyrica Caps 100mg UD100	Brand	FDA	01/03/2023	69.35	1060.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101668	Lyrica Caps 150mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101641	Lyrica Caps 150mg UD100	Brand	FDA	01/03/2023	69.35	1060.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101768	Lyrica Caps 200mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101968	Lyrica Caps 225mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101268	Lyrica Caps 25mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101868	Lyrica Caps 300mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101368	Lyrica Caps 50mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101341	Lyrica Caps 50mg UD100	Brand	FDA	01/03/2023	69.35	1060.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101468	Lyrica Caps 75mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101441	Lyrica Caps 75mg UD100	Brand	FDA	01/03/2023	69.35	1060.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071102701	Lyrica CR Tabs 165mg 30s	Brand	FDA	01/03/2023	32.50	496.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071102901	Lyrica CR Tabs 330mg 30s	Brand	FDA	01/03/2023	32.50	496.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071102601	Lyrica CR Tabs 82.5mg 30s	Brand	FDA	01/03/2023	32.50	496.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071102001	Lyrica Oral Solution 20mg/mL 473 mL	Brand	FDA	01/03/2023	79.45	1214.38	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071080324	Neurontin Caps 100mg 100s	Brand	FDA	01/03/2023	18.03	275.64	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071080524	Neurontin Caps 300mg 100s	Brand	FDA	01/03/2023	45.09	689.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071080624	Neurontin Caps 400mg 100s	Brand	FDA	01/03/2023	54.09	826.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071201247	Neurontin Oral Solution 250mg/5mL 470mL	Brand	FDA	01/03/2023	32.03	489.57	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071201244	Neurontin Oral Solution 250mg/5mL 470mL (DC)	Brand	FDA	01/03/2023	32.03	489.57	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00071-2012-44 is a discontinued NDC effective 07/12/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071051324	Neurontin Tabs 600mg 100s	Brand	FDA	01/03/2023	85.65	1309.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071040124	Neurontin Tabs 800mg 100s	Brand	FDA	01/03/2023	102.77	1570.87	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071041724	Nitrostat Sublingual Tabs 0.3mg 100s	Brand	FDA	01/03/2023	4.62	70.56	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071041824	Nitrostat Sublingual Tabs 0.4mg 100s	Brand	FDA	01/03/2023	4.62	70.56	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071041813	Nitrostat Sublingual Tabs 0.4mg 100s (Convenience Pack)	Brand	FDA	01/03/2023	10.07	153.95	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071041924	Nitrostat Sublingual Tabs 0.6mg 100s	Brand	FDA	01/03/2023	4.62	70.56	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069154068	Norvasc Tabs 10mg 90s	Brand	FDA	01/03/2023	65.13	995.52	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069154041	Norvasc Tabs 10mg UD100	Brand	FDA	01/03/2023	72.36	1106.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069152068	Norvasc Tabs 2.5mg 90s	Brand	FDA	01/03/2023	47.50	726.13	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069153072	Norvasc Tabs 5mg 300s	Brand	FDA	01/03/2023	158.35	2420.45	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069153068	Norvasc Tabs 5mg 90s	Brand	FDA	01/03/2023	47.50	726.13	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069153041	Norvasc Tabs 5mg UD100	Brand	FDA	01/03/2023	52.78	806.77	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049233045	Relpax Tabs 20mg 6s	Brand	FDA	01/03/2023	30.19	461.53	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049234005	Relpax Tabs 40mg 12s	Brand	FDA	01/03/2023	60.39	923.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049234045	Relpax Tabs 40mg 6s	Brand	FDA	01/03/2023	30.19	461.53	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069033801	Revatio Injection 0.8mg/mL 12.5mL	Brand	FDA	01/03/2023	16.92	258.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069033621	Revatio Oral Powder for Suspension 10mg/mL 112mL	Brand	FDA	01/03/2023	665.53	10173.06	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069419068	Revatio Tabs 20mg 90s	Brand	FDA	01/03/2023	346.85	5301.85	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00013830304	Xalatan Ophthalmic Drops 0.005% 2.5mL	Brand	FDA	01/03/2023	16.47	251.70	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009002901	Xanax Tabs 0.25mg 100s	Brand	FDA	01/03/2023	33.94	518.84	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009002902	Xanax Tabs 0.25mg 500s	Brand	FDA	01/03/2023	169.71	2594.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009005501	Xanax Tabs 0.5mg 100s	Brand	FDA	01/03/2023	42.29	646.39	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009005503	Xanax Tabs 0.5mg 500s	Brand	FDA	01/03/2023	211.44	3231.98	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009009001	Xanax Tabs 1mg 100s	Brand	FDA	01/03/2023	56.43	862.51	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009009004	Xanax Tabs 1mg 500s	Brand	FDA	01/03/2023	282.13	4312.52	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009009401	Xanax Tabs 2mg 100s	Brand	FDA	01/03/2023	95.94	1466.49	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009005707	Xanax XR Tabs 0.5mg 60s	Brand	FDA	01/03/2023	39.25	599.94	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009005907	Xanax XR Tabs 1mg 60s	Brand	FDA	01/03/2023	48.84	746.52	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009006607	Xanax XR Tabs 2mg 60s	Brand	FDA	01/03/2023	64.82	990.82	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009006807	Xanax XR Tabs 3mg 60s	Brand	FDA	01/03/2023	97.22	1486.10	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049005001	Zoloft Oral Solution 20mg/mL 60mL	Brand	FDA	01/03/2023	18.58	284.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049491030	Zoloft Tabs 100mg 30s	Brand	FDA	01/03/2023	27.03	413.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049491041	Zoloft Tabs 100mg UD100	Brand	FDA	01/03/2023	90.11	1377.44	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049496030	Zoloft Tabs 25mg 30s	Brand	FDA	01/03/2023	27.03	413.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049490030	Zoloft Tabs 50mg 30s	Brand	FDA	01/03/2023	27.03	413.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049490041	Zoloft Tabs 50mg UD100	Brand	FDA	01/03/2023	90.11	1377.44	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000066	ViiV Healthcare	03/31/2023	49702024613	DOVATO TAB 50-300MG - 30 tablets per bottle	Brand	FDA	01/01/2023	157.54	2809.73	01/24/2031	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702024213	JULUCA TAB 50-25MG - 30 tablets per bottle	Brand	FDA	01/01/2023	185.89	3315.31	01/24/2031	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702025537	TIVICAY PD TAB 5MG - 60 tablets per bottle	Brand	FDA	01/01/2023	23.90	426.19	12/08/2029	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702022613	TIVICAY TAB 10MG - 30 tablets per bottle	Brand	FDA	01/01/2023	23.90	426.19	12/08/2029	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702022713	TIVICAY TAB 25MG - 30 tablets per bottle	Brand	FDA	01/01/2023	59.74	1065.43	12/08/2029	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702022813	TIVICAY TAB 50MG - 30 tablets per bottle	Brand	FDA	01/01/2023	119.48	2130.86	12/08/2029	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702023113	TRIUMEQ TAB - 30 tablets per bottle	Brand	FDA	01/01/2023	198.34	3537.40	12/08/2029	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000314	VistaPharm Inc	12/31/2023	66689077508	Phenytoin Oral Suspension 125 MG/5ML - 237mL Bottle	Generic	FDA	10/26/2023	50.97	75.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000314	VistaPharm Inc	12/31/2023	66689003650	Phenytoin Oral Suspension 125 MG/5ML - 4mL cup - 50ct	Generic	FDA	10/26/2023	122.42	367.26	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000314	VistaPharm Inc	12/31/2023	66689003601	Phenytoin Oral Suspension 125 MG/5ML - 4mL cup (unit dose)	Generic	FDA	10/26/2023	2.45	7.35	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None